Search

Displaying results 6221 - 6230 of 9702 in total
  1. Drug

    XEN-D0501

    go.drugbank.com/drugs/DB18673
    Investigational

    XEN-D0501 is a tetrahydronaphthyl urea-based selective TRPV1 antagonist being investigated for the treatment of erythromelalgia.

  2. Drug

    Acimtamig

    go.drugbank.com/drugs/DB18674
    Investigational

    Acimtamig is a tetravalent bispecific chimeric anti-human CD30 x anti-human CD16A recombinant antibody construct.

  3. Drug

    EDIT-101

    go.drugbank.com/drugs/DB18687
    Investigational

    EDIT-101 is a recombinant adeno-associated virus pseudotyped with serotype 5 viral capsid encoding CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats associated protein 9) gene editing

    Synonyms: a recombinant adeno-associated virus pseudotyped with serotype 5 viral capsid encoding CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats associated protein 9) gene editing constructs
  4. Drug

    TZ-101

    go.drugbank.com/drugs/DB18690
    Experimental

    TZ-101 composes of [GDP-L-fucose] and fucosyltransferase VI

  5. Drug

    RC88

    go.drugbank.com/drugs/DB18697
    Experimental

    RC88 is an antibody-drug conjugate comprising a humanized anti-mesothelin monoclonal antibody conjugated to monomethyl auristatin E (MMAE).

  6. Drug

    Chikungunya vaccine (live, attenuated)

    go.drugbank.com/drugs/DB18701
    ApprovedInvestigational

    Chikungunya virus (CHIKV) is a member of the Alphavirus genus that was first identified in Tanzania in 1952.[A262051] It is spread primarily by the bite of infected mosquitos of the _Aedes_ genus.

  7. Drug

    SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)

    go.drugbank.com/drugs/DB18705
    Approved

    Bimervax is an adjuvanted non-mRNA COVID-19 vaccine utilizing a SARS-CoV-2 recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer. … [L48902,L48907] Bimervax was issued marketing authorization in the EU in March 2023 for use as a booster dose in patients who have previously received an mRNA COVID-19 vaccine.[L48907]

  8. Drug

    Berdazimer

    go.drugbank.com/drugs/DB18712
    Approved

    Berdazimer is a polymeric substance consisting of a polysiloxane backbone (Si-O-Si bonds) with covalently bound N-diazeniumdiolate nitric oxide (NO) donors. … [A262960] Berdazimer was previously investigated as a potential treatment for molluscum contagiosum, a viral cutaneous infection mainly affecting children, sexually active adults, and immunocompromised

  9. Drug

    Recombinant stabilized RSV A prefusion F antigen

    go.drugbank.com/drugs/DB18713
    ApprovedInvestigational

    Recombinant stabilized RSV B prefusion F antigen is one component of a bivalent respiratory syncytial virus (RSV) vaccine called Abrysvo. … The vaccine comprises two antigens - the other being [recombinant stabilized RSV A prefusion F antigen] - which have been expressed in Chinese hamster ovary cell lines and then purified and lyophilized

    Synonyms: RSV subgroup A stabilized prefusion F protein, Recombinant stabilized RSV A prefusion F antigen
  10. Drug

    rAAV1-CB-hAAT

    go.drugbank.com/drugs/DB18724
    Investigational

    rAAV1-CB-hAAT is a recombinant adeno-associated virus alpha 1-antitrypsin vector.